Retro Biosciences has unveiled three therapeutic approaches targeting cellular drivers of aging, according to the company
The first strategy involves an oral small‑molecule drug designed to enhance neuronal “cell waste” clearance via autophagy. The company said that the therapy will enter human trials this year in Australia, aiming to slow neurodegenerative processes related to Alzheimer’s disease
A second approach focuses on replacing aged microglia—brain immune cells—inflammatory dysregulation. Retro Biosciences claims that removing dysfunctional microglia and substituting them with younger ones could counteract neuroinflammation, although the company did not disclose technical specifics
The third intervention targets hematopoietic stem cell rejuvenation. The company said that it plans to generate fresh blood stem cells using Yamanaka factors and reintroduce them to replace old, dysfunctional stem cells. Initially aimed at treating blood disorders like aplastic anemia, it could ultimately address age‑related immune decline
Retro Biosciences highlighted the use of AI‑driven platforms to accelerate its R&D pipeline. Founded in 2021 and backed by Sam Altman, the company aims to extend healthy human lifespan by a decade
These three interventions are progressing rapidly toward clinical evaluation, marking a significant step in the company’s multi‑pronged strategy against age‑related cellular deterioration
